As concerns about Gilead Sciences (GILD) mount, Maxim’s Jason Kolbert are bullish on the biotech giant’s HIV franchise but not enough to change his Hold rating on the stock:
We recently spoke with GILD management about the launch of Genvoya and other HIV products. Our model now factors in our forecast for patient switch trends from other Gilead products....More>>>
U.S. stocks fell on Wednesday, slumping in a broad decline as the markets multiweek rallywhich has taken indexes to repeated records and the Dow within mere points of the 20,000 milestonestalled.
All 11 of the S&P 500s primary sectors ended lower on the day, while the benchmark index itself suffered its biggest one-day point and percentage drop since October. Financials and materials,....More>>>